A small business owner describes his experience with buying health benefit for his employees through the Affordable Care Act plans.
Every November, I return to my annual task of making a decision about health insurance. I’ve been offering this benefit to my employees for more than 20 years, and some aspects are predictable (cost increases) while others are different every year (my choice of plans, the consequences of dropping coverage).
Last year, obviously, was my first look at the world of Affordable Care Act (ACA) plans, and I ended up spending way too much time trying to figure out what to do. I kept at the task in part because I knew that, given my ability to share what I found with You’re the Boss readers, the time I spent was likely to help other bosses, too.
If you have also decided to offer insurance to your employees, and you don’t feel as though you have a good grasp of how it all works, you might want to take a look at 3 posts I wrote last year: one on how health plans work, one on how premiums vary with age under the ACA, and one on how to evaluate your out-of-pocket healthcare costs.
Read the complete article in The New York Times: http://nyti.ms/11ZFjJi
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More